Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Harvard Bioscience Company

HBIO
US4169061052
578107

Price

2.47
Today +/-
+0.07
Today %
+3.29 %
P

Harvard Bioscience stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Harvard Bioscience stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Harvard Bioscience stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Harvard Bioscience stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Harvard Bioscience's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Harvard Bioscience Stock Price History

DateHarvard Bioscience Price
10/18/20242.47 undefined
10/17/20242.39 undefined
10/16/20242.44 undefined
10/15/20242.45 undefined
10/14/20242.49 undefined
10/11/20242.53 undefined
10/10/20242.32 undefined
10/9/20242.37 undefined
10/8/20242.40 undefined
10/7/20242.40 undefined
10/4/20242.40 undefined
10/3/20242.46 undefined
10/2/20242.56 undefined
10/1/20242.54 undefined
9/30/20242.69 undefined
9/27/20242.72 undefined
9/26/20242.66 undefined
9/25/20242.66 undefined
9/24/20242.70 undefined
9/23/20242.64 undefined
9/20/20242.75 undefined

Harvard Bioscience Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Harvard Bioscience, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Harvard Bioscience from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Harvard Bioscience’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Harvard Bioscience. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Harvard Bioscience’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Harvard Bioscience’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Harvard Bioscience’s growth potential.

Harvard Bioscience Revenue, EBIT and net profit per share

DateHarvard Bioscience RevenueHarvard Bioscience EBITHarvard Bioscience Net Income
2026e125.46 M undefined16.42 M undefined11.12 M undefined
2025e108.99 M undefined6.12 M undefined6.67 M undefined
2024e106.15 M undefined5.2 M undefined5.19 M undefined
2023112.25 M undefined2.29 M undefined-3.42 M undefined
2022113.3 M undefined-4.7 M undefined-9.5 M undefined
2021118.9 M undefined3.4 M undefined-300,000 undefined
2020102.1 M undefined200,000 undefined-7.8 M undefined
2019116.2 M undefined2.8 M undefined-4.7 M undefined
2018120.8 M undefined4.8 M undefined-2.9 M undefined
201777.4 M undefined-600,000 undefined-900,000 undefined
2016104.5 M undefined-1.1 M undefined-4.3 M undefined
2015108.7 M undefined-900,000 undefined-19 M undefined
2014108.7 M undefined6.8 M undefined2.4 M undefined
2013105.2 M undefined3.7 M undefined-1.8 M undefined
2012111.2 M undefined8.1 M undefined2.4 M undefined
2011108.9 M undefined8.9 M undefined3.8 M undefined
2010108.2 M undefined10.7 M undefined19 M undefined
200985.8 M undefined8.6 M undefined7.2 M undefined
200888 M undefined10.1 M undefined1.7 M undefined
200783.4 M undefined9.5 M undefined-1.4 M undefined
200676.2 M undefined8.7 M undefined-2.3 M undefined
200567.4 M undefined7.9 M undefined-31.9 M undefined
200464.7 M undefined8.4 M undefined2.3 M undefined

Harvard Bioscience Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e
81112263040575264677683888510810811110510810810477120116102118113112106108125
-37.509.09116.6715.3833.3342.50-8.7723.084.6913.439.216.02-3.4127.06-2.78-5.412.86--3.70-25.9655.84-3.33-12.0715.69-4.24-0.88-5.361.8915.74
50.0054.5550.0046.1546.6750.0049.1246.1548.4449.2550.0048.1947.7348.2447.2246.3046.8544.7645.3744.4446.1550.6555.8355.1756.8656.7854.8758.93---
46612142028243133384042415150524749484839676458676266000
1221-1013787891081088360-104203-425616
12.5018.1816.673.85-33.332.505.2613.4612.5010.4510.5310.8411.369.419.267.417.212.865.56--0.96-3.331.72-2.54-3.541.794.725.5612.80
010-29-50-5042-31-2-1171932-12-19-40-2-4-70-9-35611
----72.41-90.00---50.00-1,650.00-93.55-50.00-200.00600.00171.43-84.21-33.33-150.00-300.00-1,050.00-78.95--100.0075.00---66.67-266.6720.0083.33
10.317.55.65.6825.827.630.731.130.831.131.431.429.929.429.829.830.433.233.634.234.836.537.838.640.341.442.42000
-------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Harvard Bioscience Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Harvard Bioscience is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
19981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                   
12.435.829.415.38.213.97.69.417.913.716.619.717.920.725.814.16.75.65.28.28.38.37.84.54.28
1.74.24.76.513.919.118.510.113.314.815.114.415.415.114.413.916.117.515.713.421.520.717.821.816.716.1
00.21.21.10.51.3000002.22.22.54.63.84.83.94.23.73.12.53.34.43.53.94
1.72.93.7615.524.725.59.110.71511.914.415.818.217.815.820.522.32016.825.122.122.327.626.424.72
0.71.71.51.83.32.53.528.119.96.72.80.65.43.91.61.51.5008.4000000
5.111.446.944.848.555.861.454.953.354.443.548.258.557.659.160.85750.445.547.557.953.651.761.651.149.04
11.61.73.55.96.77.144.64.53.23.53.13.14.64.45.25.94.33.75.913.211.710.39.28.75
00000000000000000000000000
00000000000000000000000000
0.20.20.10.120.328.227.411.210.51210.222.423.223.622.520.322.422.118.711.345.838.433.227.42116.04
0.96.69.633.231.136.342.521.12427.623.532.133.434.236.236.639.840.43836.357.357.458.657.756.357.07
0.110.50.81.91.41.50.40.90.40.816.58.111.313.411.41.11.310.51.82.31.15.47.86.47
2.29.411.937.659.272.678.536.74044.537.75966.26974.674.778.869.562.361.8110.8111.3104.6100.894.388.33
7.320.858.882.4107.7128.4139.991.693.398.981.2107.2124.7126.6133.7135.5135.8119.9107.8109.3168.7164.9156.3162.4145.4137.37
                                                   
1.52.60.30.30.30.30.40.40.40.40.40.40.40.40.40.40.40.40.40.40.40.40.40.50.50.43
03.3131.6151.5170.7172.4173.5173.7176179.2182.1184.9187.9191.2196.6202.4206.7211.5215.1218.8226.4229.2232.4225.7229232.44
1.4-28.4-78.4-83.6-82.9-78.6-76.3-108.1-110-111.4-109.7-102.5-83.4-79.6-77.3-95-92.7-111.7-116-117-119.9-124.6-132.4-132.7-142.2-145.61
1.531.1-0.6-0.80.95.37.53.26.26.7-2.8-1.8-3.9-5.7-4.9-2.6-8.2-11.9-16.7-10.7-13.5-12.7-13.1-10-15.1-14.19
00000000000000000000000000
4.48.652.967.48999.4105.169.272.674.97081101106.3114.8105.2106.288.382.891.593.492.387.383.572.273.07
0.81.92.13.15.56.56.33.44.55.64.74.94.954.74.76.38.86.24.47.45.364.96.45.55
0.61.43.32.97.454.83.14.24.143.74.73.33.55.14.544.63.85.82.47.611.28.69.38
0.31.20.92.233.856.564.41.23.71.71.31.71.32.44.21.53.16.410.65.864.45.75
1.2303.90.70.40002.21.4000000000000000
000000000000000552.42.42.866.91.73.23.85.86
2.97.56.312.116.615.716.11314.716.311.312.311.39.69.916.118.219.414.714.125.625.221.125.323.226.54
0.65.100.60.412.816.58.535.60.113.31816.31319.816.516.411.4954.846.946.345.14330.7
000.12.80.90.21.50.81.31.61.2210.40.30.21.33.86.42.72.321.91.60.60.78
00001.311.40.92.31.22.14.44.34.96.154.633.22.83.3910.376.36.27
0.65.10.13.42.61419.410.26.68.43.419.723.321.619.42522.423.22114.560.457.958.553.749.937.75
3.512.66.415.519.229.735.523.221.324.714.73234.631.229.341.140.642.635.728.68683.179.67973.164.29
7.921.259.382.9108.2129.1140.692.493.999.684.7113135.6137.5144.1146.3146.8130.9118.5120.1179.4175.4166.9162.5145.3137.37
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Harvard Bioscience provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Harvard Bioscience's financial health and stability.

Assets

Harvard Bioscience's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Harvard Bioscience must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Harvard Bioscience after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Harvard Bioscience's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (k)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
10-29-49-5042-31-2-1171932-12-19-40-2-4-70-9-3
001123564333334433443777776
00-10000000000-1100-21150-1-200000
000-1-1-5-83002-15-1-301-4-20-3-104-1024
0133518200326882565535975898510
000100000000000001000454123
010102222122112110000000000
11224021158129161268440512891114
000-1-2-1-1-3-1-2-1-1-1-1-1-1-1-2-2-10-1-1-1-1-1-2
0-1-8-5-20-12-22-10-1-3-6-2-22-8-7-40-13-700-530-1-1-1-1
0-1,000-8,000-4,000-17,000-10,000-21,000-7,0000-1,000-5,0000-20,000-7,000-5,000-2,0001,000-11,000-4,0001,0000-52,00000000
000000000000000000000000000
006-83-3113-8-52-6114-1-311-3-2-5-148-7-50-1-10
000445010000-1-2-40232200400300
006369-3134-7-53-790-1-10-10-4-153-7-70-2-12
-----------------15.00-------2.00-3.00-1.00-2.00
000000000000000000000000000
00133-6-14-75-408-423-125-11-7-102000-30
0.31.472.480.851.9-0.830.668.064.15.6910.67.3214.9711.034.896.232.382.34-2.273.90.131.876.838.18-0.09-0.4411.72
000000000000000000000000000

Harvard Bioscience stock margins

The Harvard Bioscience margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Harvard Bioscience. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Harvard Bioscience.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Harvard Bioscience's sales revenue. A higher gross margin percentage indicates that the Harvard Bioscience retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Harvard Bioscience's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Harvard Bioscience's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Harvard Bioscience's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Harvard Bioscience. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Harvard Bioscience's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Harvard Bioscience Margin History

Harvard Bioscience Gross marginHarvard Bioscience Profit marginHarvard Bioscience EBIT marginHarvard Bioscience Profit margin
2026e59.15 %13.09 %8.86 %
2025e59.15 %5.62 %6.12 %
2024e59.15 %4.9 %4.89 %
202359.15 %2.04 %-3.04 %
202254.99 %-4.15 %-8.38 %
202156.94 %2.86 %-0.25 %
202056.81 %0.2 %-7.64 %
201955.51 %2.41 %-4.04 %
201855.46 %3.97 %-2.4 %
201750.65 %-0.78 %-1.16 %
201646.32 %-1.05 %-4.11 %
201544.8 %-0.83 %-17.48 %
201445.35 %6.26 %2.21 %
201345.34 %3.52 %-1.71 %
201247.03 %7.28 %2.16 %
201146.1 %8.17 %3.49 %
201047.87 %9.89 %17.56 %
200948.6 %10.02 %8.39 %
200847.95 %11.48 %1.93 %
200748.2 %11.39 %-1.68 %
200650 %11.42 %-3.02 %
200549.41 %11.72 %-47.33 %
200448.53 %12.98 %3.55 %

Harvard Bioscience Stock Sales Revenue, EBIT, Earnings per Share

The Harvard Bioscience earnings per share therefore indicates how much revenue Harvard Bioscience has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Harvard Bioscience earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Harvard Bioscience's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Harvard Bioscience’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Harvard Bioscience's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Harvard Bioscience Revenue, EBIT and net profit per share

DateHarvard Bioscience Sales per ShareHarvard Bioscience EBIT per shareHarvard Bioscience Earnings per Share
2026e2.88 undefined0 undefined0.26 undefined
2025e2.5 undefined0 undefined0.15 undefined
2024e2.43 undefined0 undefined0.12 undefined
20232.65 undefined0.05 undefined-0.08 undefined
20222.74 undefined-0.11 undefined-0.23 undefined
20212.95 undefined0.08 undefined-0.01 undefined
20202.65 undefined0.01 undefined-0.2 undefined
20193.07 undefined0.07 undefined-0.12 undefined
20183.31 undefined0.13 undefined-0.08 undefined
20172.22 undefined-0.02 undefined-0.03 undefined
20163.06 undefined-0.03 undefined-0.13 undefined
20153.24 undefined-0.03 undefined-0.57 undefined
20143.27 undefined0.2 undefined0.07 undefined
20133.46 undefined0.12 undefined-0.06 undefined
20123.73 undefined0.27 undefined0.08 undefined
20113.65 undefined0.3 undefined0.13 undefined
20103.68 undefined0.36 undefined0.65 undefined
20092.87 undefined0.29 undefined0.24 undefined
20082.8 undefined0.32 undefined0.05 undefined
20072.66 undefined0.3 undefined-0.04 undefined
20062.45 undefined0.28 undefined-0.07 undefined
20052.19 undefined0.26 undefined-1.04 undefined
20042.08 undefined0.27 undefined0.07 undefined

Harvard Bioscience business model

Harvard Bioscience Inc was founded in 1901 and is headquartered in Holliston, Massachusetts. The company is a global leader in providing instruments, technologies, and complete systems for science and research. Harvard Bioscience has established itself as one of the leading providers of products and solutions in the fields of life sciences and health research with over 100 years of industry experience. The business model of Harvard Bioscience is focused on delivering high-quality products and solutions for research needs. The company is divided into three business segments: Life Science Research Products, Preclinical Surgical Products, and Analytical Instruments. These business segments offer a variety of products, such as instruments for cell and molecular research, gene expression analysis devices, surgical instruments, and instruments for electrophysiology. The Life Science Research segment includes the business units Harvard Apparatus, Molecular Devices, and Denville Scientific. Harvard Apparatus provides instruments for cell and molecular research, physiological instruments, and animal model systems. Molecular Devices specializes in instrumental analysis methods for cell and molecular research. Denville Scientific is a leading supplier of products for cell and molecular biology, including materials for gene and protein expression and cell culture techniques. In the Preclinical Surgical Products segment, Harvard Bioscience operates with the company Hugo Sachs Elektronik. Surgical instruments and complete systems for preclinical research are offered here. These products are popular among scientists worldwide as they have been developed for conducting research with animal models. Analytical Instruments is the segment where the company operates joint ventures to develop instruments for physical, material, and life science research. In this segment, Harvard Bioscience is primarily involved in the joint venture Wasatch Microfluidics, alongside Agilent Technologies, which specializes in the development of instruments for life sciences and biotechnology. As a provider of science and research-related instruments and devices, Harvard Bioscience has a wide range of products to help researchers and scientists enhance their work more effectively. Some of the most popular products from Harvard Bioscience include tissue processing systems, neuroprotection applications, animal model holders, and electrophysiology platforms. Harvard Bioscience also offers a range of products for quality assurance and environmental protection, such as cleanroom and protection devices for material preparation and sterilization. Overall, Harvard Bioscience Inc has an excellent reputation in the industry and is one of the world's leading companies for scientific and research-related products and services. The company constantly strives to improve its products and services and adapts to the needs of its customers. It relies on innovation and continuously works to develop and implement new technologies to meet the demands of the scientific world. Harvard Bioscience is one of the most popular companies on Eulerpool.com.

Harvard Bioscience Revenue by Segment

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Harvard Bioscience Revenue by Segment

Segmente2012
Instruments, Equipment, Software, and Accessories-
Service, Maintenance, and Warranty Contracts-
Instruments, equipment and accessories-
Service, maintenance and warranty contracts-
LSRT Reportable Segment111.17 M USD
Rmd Reportable Segment-
Unallocated-

Harvard Bioscience Revenue by Region

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Harvard Bioscience Revenue by Segment

DateAsiaCHINAEuropeGreater ChinaRest of the WorldRest Of The WorldSegment, Geographical, GermanySegment, Geographical, United KingdomSegment, Geographical, United StatesTotalUnited States
2023--32.8 M USD18.49 M USD12.76 M USD-----48.21 M USD
2022--30.69 M USD16.39 M USD16.34 M USD-----49.91 M USD
2021-24.82 M USD35.77 M USD-8.49 M USD-----49.83 M USD
202023.88 M USD-29.94 M USD-6.22 M USD-----42.05 M USD
2018-----8.57 M USD13.19 M USD13.69 M USD79.61 M USD--
2017-----9.48 M USD11.16 M USD15.04 M USD66.2 M USD101.88 M USD-
2016-----9.44 M USD13.48 M USD16.42 M USD65.18 M USD104.52 M USD-
2015-----10.09 M USD15.76 M USD18.05 M USD64.77 M USD108.66 M USD-
2014-----20.18 M USD-24.75 M USD63.73 M USD108.66 M USD-
2013-----18.24 M USD-23.12 M USD63.81 M USD--
2012-----18.84 M USD-27.14 M USD65.19 M USD--

Harvard Bioscience SWOT Analysis

Strengths

Harvard Bioscience Inc has established itself as a leading player in the bioscience industry, with a wealth of knowledge and experience in developing and manufacturing innovative scientific instruments and tools. This expertise gives the company a competitive advantage in understanding the needs of its target market and providing tailored solutions.

The company offers a wide range of high-quality products, including laboratory equipment, consumables, and specialized research tools. Harvard Bioscience’s diverse product portfolio enables it to serve various segments within the bioscience industry, catering to different customer requirements and maximizing revenue potential.

Harvard Bioscience Inc invests significantly in research and development activities to drive product innovation and stay ahead of the market. Its strong R&D capabilities enable the company to introduce cutting-edge technologies and solutions that meet emerging customer demands, enhancing its competitive position.

Weaknesses

A significant portion of Harvard Bioscience's revenue comes from a few key customers. This dependency poses a risk to the company as any loss of these customers or decline in their orders could have a substantial impact on its financial performance. Diversifying the customer base would help mitigate this vulnerability.

While Harvard Bioscience has a global customer base, its geographic presence remains relatively limited. This concentration exposes the company to regional economic factors and regulatory changes in specific markets. Expanding into new geographies would reduce the company's dependence on any single market and create additional growth opportunities.

Opportunities

The global bioscience industry is experiencing a rapid expansion, driven by increased investments in research and development activities in various sectors, including pharmaceuticals, biotechnology, and academia. This growth presents Harvard Bioscience with opportunities to capitalize on rising demand for its research tools and equipment.

The continuous advancements in fields such as genomics, proteomics, and molecular biology provide Harvard Bioscience with an opportunity to develop and introduce innovative products that cater to these evolving research needs. By staying at the forefront of technological breakthroughs, the company can gain a competitive edge.

Threats

The bioscience industry is intensely competitive, with numerous companies vying for market share. Harvard Bioscience faces competition from both established players and emerging startups. This competitive landscape puts pressure on pricing, requires continuous innovation, and increases the challenges of maintaining market leadership.

The bioscience industry is subject to strict regulations and compliance requirements, which can create barriers to entry and affect product development timelines. Harvard Bioscience must remain compliant with these regulations to ensure the quality and safety of its products while also navigating the associated costs and complexities.

The global economic uncertainty and market volatility can impact Harvard Bioscience's business, as spending on research and development activities may fluctuate during economic downturns. The company must be prepared to adapt its strategies and manage its resources effectively in response to changing market conditions.

Harvard Bioscience Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Harvard Bioscience historical P/E ratio, EBIT multiple, and P/S ratio

Harvard Bioscience shares outstanding

The number of shares was Harvard Bioscience in 2023 — This indicates how many shares 42.42 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Harvard Bioscience earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Harvard Bioscience's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Harvard Bioscience’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Harvard Bioscience's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Harvard Bioscience.

Harvard Bioscience latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20240.05 0  (-100 %)2024 Q2
3/31/20240.02 0.02  (-15.97 %)2024 Q1
12/31/20230.05 0.04  (-21.57 %)2023 Q4
9/30/20230.04 0.01  (-75.49 %)2023 Q3
6/30/20230.06 0.04  (-38.08 %)2023 Q2
3/31/20230.05 0.06  (17.65 %)2023 Q1
12/31/20220.03 0.04  (17.65 %)2022 Q4
9/30/20220.07 -0.01  (-114.71 %)2022 Q3
6/30/20220.06 0.05  (-18.3 %)2022 Q2
3/31/20220.05 0.04  (-26.47 %)2022 Q1
1
2
3
4
5
...
8

Eulerpool ESG Scorecard© for the Harvard Bioscience stock

Eulerpool World ESG Rating (EESG©)

16/ 100

🌱 Environment

17

👫 Social

17

🏛️ Governance

13

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
❌
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety❌
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Harvard Bioscience shareholders

%
Name
Stocks
Change
Date
6.73992 % B. Riley Asset Management, LLC2,939,278-323,71712/31/2023
6.69120 % Punch & Associates Investment Management, Inc.2,918,034-5,00012/31/2023
6.16841 % BlackRock Institutional Trust Company, N.A.2,690,044177,30212/31/2023
5.86448 % Harvey Partners, LLC2,557,500012/31/2023
5.29379 % AMH Equity, Ltd.2,308,622201,9523/18/2024
4.82130 % The Vanguard Group, Inc.2,102,57138,16912/31/2023
4.41558 % Dimensional Fund Advisors, L.P.1,925,635-8,33112/31/2023
4.30807 % Green (James W)1,878,749585,2373/12/2024
4.22720 % Granahan Investment Management, LLC1,843,484107,91212/31/2023
3.32683 % Royce Investment Partners1,450,82940,20012/31/2023
1
2
3
4
5
...
10

Harvard Bioscience Executives and Management Board

Mr. James Green64
Harvard Bioscience Chairman of the Board, President, Chief Executive Officer (since 2015)
Compensation 2.33 M
Mr. Bertrand Loy57
Harvard Bioscience Lead Independent Director
Compensation 192,000
Mr. Alan Edrick55
Harvard Bioscience Independent Director
Compensation 179,500
Mr. Thomas Loewald60
Harvard Bioscience Independent Director
Compensation 174,000
Ms. Katherine Eade49
Harvard Bioscience Independent Director
Compensation 165,000
1
2

Most common questions regarding Harvard Bioscience

What values and corporate philosophy does Harvard Bioscience represent?

Harvard Bioscience Inc represents a set of core values and a strong corporate philosophy. The company is committed to providing innovative solutions for life science research and advancing scientific discovery. Harvard Bioscience Inc prioritizes integrity, collaboration, and excellence in every aspect of its operations. With a focus on customer satisfaction, the company strives to deliver cutting-edge technologies and exceptional service to researchers worldwide. Through its dedication to promoting scientific advancement and improving the understanding of life sciences, Harvard Bioscience Inc has established itself as a trusted and reliable partner in the research community.

In which countries and regions is Harvard Bioscience primarily present?

Harvard Bioscience Inc primarily operates in the United States, with headquarters in Holliston, Massachusetts. The company also has a presence in Canada, Europe, and Asia, serving customers globally. With a focus on providing advanced tools and solutions for life science research, Harvard Bioscience Inc has established itself as a leading provider of innovative products and services in the field.

What significant milestones has the company Harvard Bioscience achieved?

Harvard Bioscience Inc has achieved several significant milestones. The company successfully expanded its product portfolio and strengthened its global presence through strategic acquisitions. They developed innovative technologies and solutions, enhancing their position as a leading provider of scientific instruments. Harvard Bioscience Inc also established collaborations with renowned research institutions and industry partners, fostering scientific advancements and knowledge sharing. The company's relentless commitment to research and development enabled them to introduce groundbreaking products that revolutionized various scientific disciplines. Harvard Bioscience Inc's commitment to excellence and continuous innovation has propelled them to become a trusted name in the scientific community.

What is the history and background of the company Harvard Bioscience?

Harvard Bioscience Inc is a leading global developer, manufacturer, and marketer of specialized products and technologies that advance life science research. Established in 1901, the company has a rich history of innovation and has been at the forefront of scientific advancements. With a focus on providing cutting-edge tools and solutions, Harvard Bioscience Inc has become a trusted partner for researchers and scientists worldwide. Their dedication to delivering high-quality products and services has enabled them to establish a strong presence in the life science industry. Today, Harvard Bioscience Inc continues to drive innovation and shape the future of scientific discovery.

Who are the main competitors of Harvard Bioscience in the market?

The main competitors of Harvard Bioscience Inc in the market include companies such as Thermo Fisher Scientific, Bio-Rad Laboratories, and PerkinElmer Inc. These companies operate in the life sciences and biotechnology industries, offering a range of products and solutions that compete with Harvard Bioscience Inc's offerings. By providing innovative scientific instruments, tools, and services, these competitors create a competitive landscape within the market. Harvard Bioscience Inc continually faces the challenge of distinguishing its products and maintaining a competitive edge against these major players in the industry.

In which industries is Harvard Bioscience primarily active?

Harvard Bioscience Inc is primarily active in the life sciences industry.

What is the business model of Harvard Bioscience?

The business model of Harvard Bioscience Inc is focused on providing innovative tools and solutions to life science researchers. The company specializes in developing and manufacturing scientific instruments, systems, and lab supplies that are used in drug discovery, disease research, and other biomedical applications. These products cater to a wide range of research fields, including cell biology, neurobiology, stem cell research, and physiology. Harvard Bioscience Inc aims to support scientists and enhance their research capabilities by delivering high-quality products that enable efficient and accurate experimentation.

What is the P/E ratio of Harvard Bioscience 2024?

The Harvard Bioscience P/E ratio is 20.19.

What is the P/S ratio of Harvard Bioscience 2024?

The Harvard Bioscience P/S ratio is 0.99.

What is the Quality Investing of Harvard Bioscience?

The Quality Investing for Harvard Bioscience is 1/10.

What is the revenue of Harvard Bioscience 2024?

The expected Harvard Bioscience revenue is 106.15 M USD.

How high is the profit of Harvard Bioscience 2024?

The expected Harvard Bioscience profit is 5.19 M USD.

What is the business model of Harvard Bioscience

Harvard Bioscience Inc is a globally operating company specializing in the sale of scientific instruments and devices for the life sciences. The company is divided into three business segments: Life Science Research, Analytical Instruments, and Bioscience Tools. In the Life Science Research segment, Harvard Bioscience offers a wide range of instruments for the study of cells, tissues, and organs. This includes devices for cell culture, DNA transfection, microinjection, and cell monitoring. Products for tissue research include cell slicers, tissue homogenizers and disruptors, as well as sample manipulation devices. Harvard Bioscience also offers organ perfusion systems, organ baths, and organ isolation devices for organ research. The Analytical Instruments segment focuses on instruments for the analysis of biological samples. This includes pH meters, conductivity meters, pipettes, density meters, and osmometers. The Bioscience Tools segment offers a broad portfolio of tools and consumables for the life sciences. This includes micro pipettes, microinjection needles, cell culture plates, and PCR tubes. A key concept of Harvard Bioscience is the high quality of its products. Most instruments and devices are developed and manufactured in their own production facilities. The company emphasizes strict quality testing and control, as well as compliance with international norms and standards. Harvard Bioscience sells its products worldwide through a network of distribution partners and direct sales channels. The majority of customers are research institutes, universities, biotechnology and pharmaceutical companies, as well as government organizations. The company works closely with its customers and partners to customize products to meet their needs and fulfill specific requirements. A key growth strategy of Harvard Bioscience is continuous innovation and development of its products. The company invests a significant portion of its revenue in research and development each year. By acquiring companies that develop innovative biotechnological technologies, the company aims to strengthen its strong position in the industry and expand its presence in the international market. Overall, the business model of Harvard Bioscience is focused on providing high-quality scientific instruments and technologies for the life sciences. The company's emphasis on research and development and collaboration with customers and partners distinguish it and ensure continuous growth and success. Answer: The Harvard Bioscience Inc is a global company specializing in selling scientific instruments and devices for the life sciences. They have three business segments: Life Science Research, Analytical Instruments, and Bioscience Tools. They offer a wide range of instruments for cell, tissue, and organ research. They also have instruments for analyzing biological samples and a portfolio of tools and consumables for the life sciences. They focus on high-quality products and comply with international standards. They sell their products worldwide through various channels and work closely with customers and partners. Continuous innovation and development are important to their growth strategy.

What is the Harvard Bioscience dividend?

Harvard Bioscience pays a dividend of 0 USD distributed over payouts per year.

How often does Harvard Bioscience pay dividends?

The dividend cannot currently be calculated for Harvard Bioscience or the company does not pay out a dividend.

What is the Harvard Bioscience ISIN?

The ISIN of Harvard Bioscience is US4169061052.

What is the Harvard Bioscience WKN?

The WKN of Harvard Bioscience is 578107.

What is the Harvard Bioscience ticker?

The ticker of Harvard Bioscience is HBIO.

How much dividend does Harvard Bioscience pay?

Over the past 12 months, Harvard Bioscience paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Harvard Bioscience is expected to pay a dividend of 0 USD.

What is the dividend yield of Harvard Bioscience?

The current dividend yield of Harvard Bioscience is .

When does Harvard Bioscience pay dividends?

Harvard Bioscience pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Harvard Bioscience?

Harvard Bioscience paid dividends every year for the past 0 years.

What is the dividend of Harvard Bioscience?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Harvard Bioscience located?

Harvard Bioscience is assigned to the 'Health' sector.

Wann musste ich die Aktien von Harvard Bioscience kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Harvard Bioscience from 10/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/19/2024.

When did Harvard Bioscience pay the last dividend?

The last dividend was paid out on 10/19/2024.

What was the dividend of Harvard Bioscience in the year 2023?

In the year 2023, Harvard Bioscience distributed 0 USD as dividends.

In which currency does Harvard Bioscience pay out the dividend?

The dividends of Harvard Bioscience are distributed in USD.

All fundamentals about Harvard Bioscience

Our stock analysis for Harvard Bioscience Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Harvard Bioscience Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.